share_log

Moderna to Present at Upcoming Conferences in December 2024

Moderna to Present at Upcoming Conferences in December 2024

moderna將在2024年12月的即將召開會議上進行介紹
Accesswire ·  20:00

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

美國馬薩諸塞州劍橋 / ACCESSWIRE / 2024年11月25日 / moderna, inc. (納斯達克:MRNA) 今天宣佈將參加以下即將舉行的投資者會議:

7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET

第七屆evercore ISI健康大會,將於12月4日星期三下午1:20(美國東部時間)舉行

Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET

派傑投資第36屆年度醫療會議,將於12月5日星期四上午10:30(美國東部時間)舉行

A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

您可以在moderna公司網站的投資者部門的"活動和演示"下找到這些演示的現場網絡廣播。每個網絡廣播的重播將在演示結束後的至少30天內存檔在moderna網站上。

About Moderna

關於現代

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna是mRNA醫學領域的領軍者。通過推動mRNA技術的進步,現代正在重新構想藥物的製造方式,爲所有人治療和預防疾病。通過在科學、技術和健康交叉領域工作十多年,公司已以前所未有的速度和效率開發出藥物,包括最早和最有效的COVID-19疫苗之一。

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna的mRNA平台使得感染性疾病、免疫治療、罕見病和自身免疫性疾病的治療和疫苗的開發成爲可能。Moderna擁有獨特的文化和全球團隊,秉持Moderna價值觀和思維方式,爲了負責任地改變人們未來的健康而努力,致力於通過mRNA藥物帶來最大的影響。有關Moderna的更多信息,請訪問modernatx.com,並在X(原Twitter)、Facebook、Instagram、YouTube和LinkedIn上與我們聯繫。

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

投資者:
Lavina Talukdar
高級副主席,投資者關係負責人
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

來源:現代RNA股份有限公司。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論